Numerous prospective clinical trials have tested the effect of BRAF and RAS mutations on the response to ICI therapy in dMMR/MSI CRC patients but all except one described above [197] did not find a significant association [41,196,197,200,201,233,234]. The gene discussed is BRAF; the disease is colorectal carcinoma.